The effectiveness of Mifurol as an adjuvant chemotherapy in colonic cancer patients has been assessed on the basis of long-term survival at various institutions. In the curative resection cases, the outcome of administrations of MMC (0.2 mg/kg x 2) + Mifurol (6-12 mg/kg/day) (group A and MMC (0.2 mg/kg x 2)+ Tegafur (12 mg/kg/day) (group B) was compared. There was no difference in the background factors or in the total amount of the alpha rugs administrated in these two groups. The five-year survival by Kaplan-Meirer's method were 56.1% and 36.1% for group A and B, respectively, the difference being particularly remarkable in Dukes C cases.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Synergistic effect of repurposed mitomycin C in combination with antibiotics against Aeromonas infection: In vitro and in vivo studies.
J Microbiol Immunol Infect
December 2024
Institute of Clinical Medicine, College of Medicine, National Cheng Kung University, Tainan, Taiwan; Department of Oncology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan; Department of Internal Medicine, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan. Electronic address:
Background: Aeromonas infections pose a significant threat associated with high mortality rates. This study investigates the potential of mitomycin C (MMC), an anticancer drug, as a novel antimicrobial agent against Aeromonas infections.
Methods: We evaluated the minimum inhibitory concentrations (MICs) of MMC and antibiotics against clinical Aeromonas isolates using broth microdilution.
Methylone regulates fear memory and amygdala activity: A potential treatment for posttraumatic stress disorder?
Prog Neuropsychopharmacol Biol Psychiatry
November 2024
Department of Medicine, MacKay Medical College, New Taipei, Taiwan; Department of Psychiatry, MacKay Memorial Hospital, Taipei, Taiwan. Electronic address:
Methylone (3,4-methylenedioxy-N-methylcathinone) is a rapid-acting entactogen that has demonstrated significant benefits for patients with post-traumatic stress disorder (PTSD) and exhibits good tolerability in phase 1 clinical trials. Despite these promising results, its preclinical effects on fear memory regulation and the underlying mechanisms remain largely unexplored. This study aims to investigate the impact of methylone on auditory fear extinction and its influence on neuronal and synaptic activity in the basolateral amygdala (BLA).
View Article and Find Full Text PDFMaternal Minocycline as Fetal Therapy in a Rat Model of Myelomeningocele.
J Surg Res
September 2024
Division of General Pediatric Surgery, Department of Surgery, Johns Hopkins School of Medicine, Baltimore, Maryland. Electronic address:
Article Synopsis
- This study explored the effects of the antibiotic minocycline on reducing inflammation and cell death in fetal rats with myelomeningocele (MMC) when administered to pregnant rats.
- Pregnant rats were treated with different substances to induce MMC in their fetuses, and then some mothers received minocycline, with their offspring's spinal cords analyzed for inflammation and cell death markers.
- The results suggested that minocycline exposure led to lower levels of inflammation and cell death markers in the fetal spinal cords, indicating its potential as a prenatal treatment for spinal cord issues associated with MMC.
Phase I studies of davoceticept (ALPN-202), a PD-L1-dependent CD28 co-stimulator and dual PD-L1/CTLA-4 inhibitor, as monotherapy and in combination with pembrolizumab in advanced solid tumors (NEON-1 and NEON-2).
J Immunother Cancer
August 2024
Alpine Immune Sciences Inc, Seattle, Washington, USA.
Article Synopsis
- - Davoceticept (ALPN-202) is an experimental treatment designed to enhance immune response by targeting PD-L1 and CTLA-4, and its effectiveness was assessed in two studies: NEON-1 (monotherapy) and NEON-2 (in combination with pembrolizumab) on patients with advanced solid tumors.
- - In NEON-1, 58 participants received varying doses of davoceticept, and in NEON-2, 29 patients received davoceticept alongside pembrolizumab, with safety and efficacy monitored through adverse events and tumor response.
- - Results indicated that 67% of participants in NEON-1 and 62% in NEON-
Inhalation of hydrogen gas protects against mitomycin-induced pulmonary veno-occlusive disease.
Respir Res
July 2024
State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangdong Key Laboratory of Vascular Disease, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, 510120, China.
Article Synopsis
- Pulmonary veno-occlusive disease (PVOD) is a severe form of pulmonary hypertension that currently has no effective treatments, prompting research into the potential benefits of inhaled hydrogen gas.
- In a study with female rats, hydrogen inhalation showed positive effects by improving heart function, reversing heart enlargement, and preventing changes in pulmonary blood vessels when administered either before or after a harmful substance (mitomycin C).
- The use of hydrogen gas decreased markers of oxidative stress and inflammation in lung tissue and serum, while also promoting protective signaling pathways, suggesting that hydrogen inhalation could help counteract the damaging effects associated with PVOD.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!